**Supplementary information**

**Custom-made questionnaire with scale ranging from 1 (very unsatisfied) to 7 (very satisfied)**

Cuestionario de Satisfacción del paciente

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | |
| **Por favor, escoja el número que mejor describa su satisfacción con Spiolto® Respimat®.** | | | | | | |
| **¿Cuál es su satisfacción general con el tratamiento con Spiolto® Respimat®?** | | | | | | |
| 1  muy insatisfecho | 2  insatisfecho | 3  un poco insatisfecho | 4  ni satisfecho  ni insatisfecho | 5  un poco satisfecho | 6  satisfecho | 7  muy satisfecho |
|  | | | | | | |
| **¿Qué tan satisfecho está usted con la inhalación del dispositivo Respimat®?** | | | | | | |
| 1  muy insatisfecho | 2  insatisfecho | 3  un poco insatisfecho | 4  ni satisfecho  ni insatisfecho | 5  un poco satisfecho | 6  satisfecho | 7  muy satisfecho |
|  | | | | | | |
| **¿Qué tan satisfecho está usted con el manejo del dispositivo de inhalación Respimat®?** | | | | | | |
| 1  muy insatisfecho | 2  insatisfecho | 3  un poco insatisfecho | 4  ni satisfecho  ni insatisfecho | 5  un poco satisfecho | 6  satisfecho | 7  muy satisfecho |

**Figure 1S. Treatment of COPD in the 6 months prior to baseline visit.**



ICS: Inhaled corticosteroids; LABA: long-acting beta 2 agonists; LAMA: long-acting muscarinic antagonists; SABA: short-acting beta-2 agonists; SAMA: short-acting muscarinic antagonists.

**Table 1S**. **Pre-specified subgroup analysis for the primary objective.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Success** | **No success** | **p-value** |
| **Previous treatment for COPD** |  |  | 0.8030 |
| - Treatment-naïve patients | 64 (65.3%) | 34 (34.7%) |  |
| - Already treated with long-acting bronchodilators | 55 (67.1%) | 27 (32.9%) |  |
| **GOLD classification of severity (2014)** |  |  |  |
| - 2 | 58 (70.7%) | 24 (29.3%) | 0.5903 |
| - 3/4 | 23 (65.7%) | 12 (34.3%) |  |
| - B | 61 (74.4%) | 21 (25.6%) | 0.6436 |
| - C/D | 67 (71.3%) | 27 (28.7%) |  |
| **Previous inhaled corticosteroids** |  |  | 0.3873 |
| - Yes | 14 (58.3%) | 10 (41.7%) |  |
| - No | 141 (67.1%) | 69 (32.9%) |  |
| **Age** |  |  | 0.7726 |
| - <65 y.o. | 52 (65.0%) | 28 (35.0%) |  |
| - ≥65 y.o. | 103 (66.9%) | 51 (33.1%) |  |
| **Exacerbations in the last 12m** |  |  | 0.1413 |
| - ≤1 | 110 (63.6%) | 63 (36.4%) |  |
| - ≥2 | 43 (74.1%) | 15 (25.9%) |  |
| **Exacerbations related to hospitalisations in the last 12m** |  |  | 0.1807 |
| - 0 | 140 (64.8%) | 76 (35.2%) |  |
| - ≥1 | 13 (81.3%) | 3 (18.8%) |  |

 **Figure 2S. Correlation between PF-10 score and overall satisfaction with the treatment with a FDC of tiotropium/olodaterol SMI.**